Mice with an OPMD-like disease treated with cystamine showed improved strength and muscle function and fewer cellular abnormalities
Scientists in the United Kingdom have found that mice carrying a genetic mutation that causes oculpharyngeal muscular dystrophy (OPMD) in humans and showing a disease resembling human OPMD benefited from treatment with a chemical called cystamine, provided in their drinking water.
About the new findings
David Rubinsztein and colleagues at the University of Cambridge announced their findings June...
Seattle resident Ken Lang (see “Like a Frog”) says he knew a disease that impairs swallowing and speaking was a possibility for him, because his father, uncle and grandmother had been affected by such a disorder.
OPMD is a form of muscular dystrophy in which symptoms usually first appear between the 30s and 60s, and primarily involve the muscles of the upper eyelids and the swallowing muscles. As these muscles weaken, patients have difficulty keeping their eyes open and find that food and liquids are increasingly hard to swallow. As OPMD progresses, it can weaken the muscles of the limbs,...
An antibody from llamas, tested in fruit flies, holds promise as a treatment for OPMD
Scientists in France and the Netherlands recently announced they've identified a promising new strategy that could potentially become a therapy for oculopharyngeal muscular dystrophy (OPMD), a form of MD that primarily weakens the eyelid and throat muscles and also can affect muscles in the limbs.
The strategy involves using an antibody (immune-system protein) derived from llamas. The antibody...